Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Molecular Devices Introduces EarlyTox Cardiotoxicity Kit

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
The EarlyTox™ Cardiotoxicity Kit is a fast, simple and reliable fluorescence-based kit for identifying cardiotoxicity of drug candidates early in the discovery process.

EarlyTox allows researchers to prioritize lead compounds and drug candidates, and direct medicinal chemistry efforts sooner, improving productivity and reducing costs associated with downstream safety testing. The kit may also enable the discovery of new cardiac drug candidates.

The EarlyTox Cardiotoxicity Kit measures changes in cytoplasmic calcium which are associated with cardiomyocyte beating. The kit combines a novel calcium sensitive dye and proprietary masking technology, resulting in the largest dynamic range and enhanced discrimination of beat pattern detail. Unlike other calcium dyes, the new dye formulation minimizes non-specific effects on beat characteristics.

The optimized calcium-sensitive dye formulation binds with calcium ions in the cell cytoplasm, enabling measurement of any changes in calcium concentration. The masking technology remains outside the cell and acts to reduce extracellular background fluorescence. When compared to traditional safety assays, this robust, high throughput assay format measures 384 samples in minutes rather than hours.

Kevin Chance, President of Molecular Devices, commented: “Highly predictive and biologically relevant in vitro assays suitable for high throughput screening are critical to improving efficiencies and reducing the high costs associated with compounds that fail during cardiac safety assessment. When paired with the FLIPR® Tetra System, and other microplate readers from Molecular Devices, the EarlyTox Cardiotoxicity Kit is a powerful tool in eliminating cardiotoxic compounds earlier in the drug discovery process."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecular Devices Partners with Roche
Partnership will develop custom Ruthenium Nano-TRF Detection Platform.
Thursday, November 06, 2014
Molecular Devices Becomes Global Distributor of IonFlux
Molecular Devices makes deal with Fluxion Biosciences to distribute their automated electrophysiology systems and associated products.
Tuesday, May 28, 2013
Molecular Devices Forms Scientific Advisory Board
Multidisciplinary team will guide product and application development to deliver maximum value to customers.
Thursday, December 27, 2012
Molecular Devices to attend ADME & Predictive Toxicology Europe
Company is to showcase its SpectraMax® Paradigm® microplate reader during the European conference in Munich, Germany, 13-14 March 2012.
Wednesday, February 29, 2012
Molecular Devices Awarded Patent for Population Patch Clamp Recording Technique
The parallel recording technique measures ionic currents from a population of cells, rather than single cells, on planar patch clamp systems and enhances ion channel assay success rates to near 100%.
Tuesday, January 10, 2012
Registration opens for RNAi and High Content Imaging 2011
Molecular Devices Inc. announces that they have opened registration for its RNAi & High Content Imaging Symposium 2011, to be held at the Oxford Spires Four Pillars, Oxford on 1st April 2011.
Tuesday, February 08, 2011
Molecular Devices Launches New Products & Customer-Focused Brand at Society for Biomolecular Sciences Meeting
New IonWorks Barracuda™ Automated High-Speed Patch Clamp System & AquaMax® 2000/4000 Microplate Washer 96 Cell-Wash Head
Thursday, April 08, 2010
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!